Biologic effects of leukocytes present in transfused cellular blood products - PubMed (original) (raw)
Review
. 1994 Sep 15;84(6):1703-21.
Affiliations
- PMID: 8080981
Free article
Review
Biologic effects of leukocytes present in transfused cellular blood products
J O Bordin et al. Blood. 1994.
Free article
Abstract
A considerable literature has accumulated over the past decade indicating that leukocytes present in allogeneic cellular blood components, intended for transfusion, are associated with adverse effects to the recipient. These include the development of febrile transfusion reactions, graft-versus-host disease, alloimmunization to leukocyte antigens, and the immunomodulatory effects that might influence the prognosis of patients with a malignancy. Moreover, it has become evident that such leukocytes may be the vector of infectious agents such as CMV, HTLV-I/II, and EBV as well as other viruses. An interesting development that has occurred coincidentally in transfusion medicine is that agencies responsible for the provision of blood products are being designated manufacturers of biologicals. The trend among manufacturers of biologicals is to try to produce pure products to provide for the specific therapeutic need of patients. Thus, with the realization that allogeneic leukocytes and their products may have adverse biologic activities, there is increasing pressure from various sources for the reduction of the leukocyte content in allogeneic blood components to minimize the occurrence of their adverse effects. Although the threshold leukocyte number below which these effects might no longer occur is still to be determined, a 2 to 3 log10 leukocyte reduction, provided by the currently available commercial leukocyte filters, has been shown to reduce the frequency of many of such reactions. On the other hand, the immunosuppressive effects produced by the infusion of allogeneic leukocytes might be beneficial for some patients, ie, for the maintenance of kidney allografts, in possibly reducing the relapse rate in patients with inflammatory bowel diseases, and in ameliorating recurrent spontaneous abortion. Moreover, therapeutic granulocyte transfusions may be of benefit in certain well-defined categories of patients infected with bacteria, yeast, and/or fungi. These include neonates with bacterial sepsis associated with bone marrow failure as well as severely neutropenic leukemic patients with an infection unresponsive to appropriate and specific antibiotic therapy. Many of the results obtained with the use of leukocyte depletion filters are tantalizing, but the actual clinical benefit of leukodepletion has not been established in most instances, because much of the available data are retrospective or from uncontrolled clinical trials. Moreover, issues of cost-effectiveness and quality control have not been considered adequately. Properly designed prospective clinical trials are essential to provide data with which to answer such questions and also to help define the optimal conditions required for the preparation of blood components ultimately destined for clinical use. Only with the availability of such data can sound decisions be made about the clinical value of leukodepletion.
Similar articles
- [Clinical applications of leukocyte filters].
Bordin JO, Fabron Júnior A. Bordin JO, et al. Rev Assoc Med Bras (1992). 1997 Jul-Sep;43(3):205-8. doi: 10.1590/s0104-42301997000300007. Rev Assoc Med Bras (1992). 1997. PMID: 9497547 Review. Portuguese. - Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy.
Bordin JO, Blajchman MA. Bordin JO, et al. Hematol Oncol Clin North Am. 1995 Feb;9(1):205-18. Hematol Oncol Clin North Am. 1995. PMID: 7737942 Review. - Mechanisms of transfusion-associated immunosuppression.
Blajchman MA, Bordin JO. Blajchman MA, et al. Curr Opin Hematol. 1994 Nov;1(6):457-61. Curr Opin Hematol. 1994. PMID: 9371323 Review. - From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.
Erhabor O, Adias TC. Erhabor O, et al. Transfus Clin Biol. 2011 Dec;18(5-6):516-26. doi: 10.1016/j.tracli.2011.06.001. Epub 2011 Oct 28. Transfus Clin Biol. 2011. PMID: 22037104 Review. - Leukocyte reduction in blood component therapy.
Lane TA, Anderson KC, Goodnough LT, Kurtz S, Moroff G, Pisciotto PT, Sayers M, Silberstein LE. Lane TA, et al. Ann Intern Med. 1992 Jul 15;117(2):151-62. doi: 10.7326/0003-4819-117-2-151. Ann Intern Med. 1992. PMID: 1605430 Review.
Cited by
- In vitro assessment of platelet storage lesion in leucoreduced random donor platelet concentrates.
Ahmed AS, Leheta O, Younes S. Ahmed AS, et al. Blood Transfus. 2010 Jan;8(1):28-35. doi: 10.2450/2009.0077-09. Blood Transfus. 2010. PMID: 20104276 Free PMC article. - Impact of allogeneic red blood cell transfusion on prognosis in soft tissue sarcoma patients. A single-centre study.
Smolle MA, Helmberg W, Matzhold EM, Barth DA, Sareban N, Szkandera J, Liegl-Atzwanger B, Leithner A, Pichler M. Smolle MA, et al. Cancer Med. 2023 Jan;12(2):1237-1246. doi: 10.1002/cam4.4989. Epub 2022 Jun 28. Cancer Med. 2023. PMID: 35762175 Free PMC article. - Biochemical storage lesions occurring in nonirradiated and irradiated red blood cells: a brief review.
Adams F, Bellairs G, Bird AR, Oguntibeju OO. Adams F, et al. Biomed Res Int. 2015;2015:968302. doi: 10.1155/2015/968302. Epub 2015 Jan 29. Biomed Res Int. 2015. PMID: 25710038 Free PMC article. Review. - Proposed mechanisms of transfusion-induced immunomodulation.
Kirkley SA. Kirkley SA. Clin Diagn Lab Immunol. 1999 Sep;6(5):652-7. doi: 10.1128/CDLI.6.5.652-657.1999. Clin Diagn Lab Immunol. 1999. PMID: 10473511 Free PMC article. Review. No abstract available. - Study protocol of the WashT Trial: transfusion with washed versus unwashed red blood cells to reduce morbidity and mortality in infants born less than 28 weeks' gestation - a multicentre, blinded, parallel group, randomised controlled trial.
Stark MJ, Collins CT, Andersen CC, Crawford TM, Sullivan TR, Bednarz J, Morton R, Marks DC, Dieng M, Owen LS, Opie G, Travadi J, Tan K, Morris S. Stark MJ, et al. BMJ Open. 2023 Jul 24;13(7):e070272. doi: 10.1136/bmjopen-2022-070272. BMJ Open. 2023. PMID: 37487676 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous